Pricing Log in Create free account
Saturday 17 October 2026 Export GTBP’s income statement to Excel — free account

GT Biopharma, Inc.

GTBP Healthcare Biotechnology

In the quarter to June 2026, EPS grew 98.9% and free cash flow fell 41.3%, each against the same quarter a year earlier.

7.03 0.33 −4.48%
Market cap
$15.2M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
−5138.41
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 15.17
Revenue 0.06
Net Income (4.76)
Free Cash Flow (14.43)
Net Debt (5.05)
Current Ratio 2.61 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E —
P/S ratio 181.94 (above 10: high)
P/B ratio 3.06
Past 5Y EPS Growth —
This Y EPS Growth 93.56% (at or above 15%: strong)
Next Y EPS Growth 25.58% (at or above 15%: strong)
Next Y revenue growth —
Next 5Y EPS Growth 65.26% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 543×, against a ten-year median of 211×; over the ten years it ranged from −65.1× in 2021 to 23,094,733× in 2016.
P/S against its own 10 years 89.39%
10-year low 10-year high
P/B against its own 10 years 99.18%
10-year low 10-year high
EV/Sales against its own 10 years 92.99%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2019 Powerpack
2018 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 14 4 7 5
Receivables — — — —
Inventory — — — —
Other — — 1 1
14 4 8 6
2023 2024 2025 Q'26
Payables 4 4 1 1
ST’ Debt — — — —
Other 1 0 0 —
7 6 2 2

Compound Annual Growth %

10y 5y 3y
Sales — 19.67% (57.10%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% (20.99%)

Revenue $m

Year
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (4) — — —
’25 (2) (3) (4) (4) (13)
’24 (4) (4) (3) (2) (13)
’23 (3) (2) (2) (2) (9)
’22 (5) (3) (3) (4) (15)
’21 (4) (4) (4) (4) (16)
’20 0 (3) (2) (2) (7)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (4) — — —
’25 (2) (3) (4) (4) (13)
’24 (4) (4) (3) (2) (13)
’23 (3) (2) (2) (2) (9)
’22 (5) (3) (3) (4) (15)
’21 (4) (4) (4) (4) (16)
’20 0 (3) (2) (2) (7)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (2.75) (3.00) — — —
’25 (8.25) (272.09) (20.75) (121.00) (167.00)
’24 (41.00) (54.25) (38.25) (41.50) (173.50)
’23 (5.24) (37.54) (45.04) (54.28) (141.00)
’22 (127.63) (75.07) (165.16) (135.13) (495.50)
’21 (1.37k) (112.61) (127.63) (390.39) (1.55k)
’20 (255.36) (3.09k) (510.71) (962.29) (4.84k)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 12,241.21 1,530.15 295.80 33.15 39.78 88.80 26.28 5.40 1.72 0.54

Analyst estimates 2026–2028

Powerpack
High 566,156.13 40,135.88 2,983.48 492.15 392.70 591.99 112.20 33.00 10.66 3.85
People
People Employees 2 5 3 2 3 8 2 2 1 1
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Income, $m
Income, $m Revenue — — — — — — — — — —
Gross margin, % 0.00 0.00 0.00 0.00 — — — — — —
EBT 10 (144) (259) (39) (28) (58) (21) (8) (13) (28)
EBT margin, % 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net income 10 (144) (259) (39) (28) (58) (21) (8) (13) (28)
Depreciation 3 5 10 1 0 — — — — —
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings 3,327,385.00 (109,037.60) (65,882.20) (8,554.47) (4,842.34) (1,546.55) (495.50) (141.00) (173.50) (167.00)
Cash flow 0.00 (4,176.92) (2,737.69) (813.11) (1,252.07) (416.16) (358.05) (164.23) (170.01) (58.57)
Capex 0.00 (3.08) (9.23) 44.44 0.00 0.00 0.00 0.00 0.00 0.00
Free cash flow 0.00 (4,180.00) (2,746.92) (768.67) (1,252.07) (416.16) (358.05) (164.23) (170.01) (58.57)
Book value 0.00 193,606.92 2,915.38 (4,291.11) (5,074.66) 584.27 276.09 138.70 (22.00) 26.24
Shares, m 0 0 0 0 0 0 0 0 0 0
Valuation, ×
Valuation, × P/E — — — — — — — — — —
P/S — — — — — — — — — —
P/B — — — — — — — — — —
EV/Sales — — — — — — — — — —
EV/FCF — — — — — — — — — —
Cash, $m
Cash, $m Operating cash flow (2) (5) (11) (4) (7) (16) (15) (9) (13) (13)
Capex — 0 0 0 — — — — — —
Free cash flow (2) (5) (11) (3) (7) (16) (15) (9) (13) (13)
Balance, $m
Balance, $m Working capital (19) (2) (14) (19) (29) 22 12 7 (2) 6
Total debt 11 0 11 13 26 0 0 — — —
Net debt 11 (1) 11 13 21 (32) (17) (14) (4) (7)
Shareholders’ equity (19) 252 11 (19) (29) 22 12 7 (2) 6
Returns, %
Returns, % ROA 24,729.11 (113.35) (185.29) (299.65) (934.32) (306.70) (85.41) (49.26) (143.53) (558.42)
ROIC 0.00 (33.74) (710.97) 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE (28.11) (123.88) (197.06) 972.88 116.09 1,541.48 (124.15) (79.10) (453.55) (1,674.31)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2015 · latest quarter Dec 2015

Charts ten years each

GT Biopharma, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
AKTX Akari Therapeutics PLC $15.5M — (loss-making) — — n/m +4.51% (above 0%: growing) 0.00% 0.00% Compare
VAXX Vaxxinity, Inc. $15.5M — (loss-making) — (loss-making) −100.23% (below 0%: shrinking) n/m +17.00% (above 0%: growing) 0.00% 0.00% Compare
MRKR MARKER THERAPEUTICS, INC. $15.3M — (loss-making) — (loss-making) +2.75% (above 0%: growing) n/m −97.84% (below 0%: shrinking) 100.00% 0.00% Compare
NCEL NewcelX Ltd. $15.3M — (loss-making) — — n/m −87.71% (below 0%: shrinking) 0.00% — Compare
GTBP GT Biopharma, Inc. $15.2M — (loss-making) — −100.00% (below 0%: shrinking) n/m −41.34% (below 0%: shrinking) 0.00% 0.00%
DARE Dare Bioscience, Inc. $14.6M — (loss-making) — (loss-making) +984.43% (above 0%: growing) n/m −30.23% (below 0%: shrinking) (70.56%) (1,582.93%) Compare
ADAPY Adaptimmune Therapeutics PLC $14.6M — (loss-making) — (loss-making) −89.33% (below 0%: shrinking) n/m −174.72% (below 0%: shrinking) 81.71% (221.45%) Compare
CNSY Cerenome, Inc. $14.3M — (loss-making) — (loss-making) −70.43% (below 0%: shrinking) n/m −31.46% (below 0%: shrinking) 100.00% (2,203.65%) Compare
TVRD Tvardi Therapeutics, Inc. $14.3M — (loss-making) — (loss-making) +20.33% (above 0%: growing) n/m −57.26% (below 0%: shrinking) 100.00% 0.00% Compare
Median of peers $15.0M — — −33.84% — −44.36% 40.86% 0.00%

All 614 Biotechnology stocks →

GT Biopharma, Inc. (GTBP) key facts

  • GT Biopharma, Inc. (GTBP) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, GTBP traded at $7.03, a market capitalization of $15.2 million.
  • Return on equity was −1,674.3% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.

GT Biopharma, Inc. (GTBP) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/GTBP · Data as of Dec 31, 2015 · For information only; not investment advice. · © 2026 stockrow.com